The calcium-sensing receptor modulates the prostaglandin E 2 pathway in intestinal inflammation.

The prostaglandin E (PGE) pathway is one of the main mediators of intestinal inflammation. As activation of the calcium-sensing receptor (CaSR) induces expression of inflammatory markers in the colon, we assessed the impact of the CaSR on the PGE pathway regulation in colon cancer cells and the colon and . We treated CaSR-transfected HT29 and Caco-2 colon cancer cell lines with different orthosteric ligands or modulators of the CaSR and measured gene expression and PGE levels. In CaSR-transfected HT29 and Caco-2 cells, the orthosteric CaSR ligand spermine and the positive allosteric CaSR modulator NPS -568 both induced an inflammatory state as measured by IL-8 gene expression and significantly increased the expression of the PGE pathway key enzymes cyclooxygenase (COX)-2 and/or prostaglandin E synthase 1 (PGES-1). Inhibition of the CaSR with the calcilytic NPS 2143 abolished the spermine- and NPS -568-induced pro-inflammatory response. Interestingly, we observed cell-line specific responses as . PGES-1 expression was affected only in HT29 but not in Caco-2 cells. Other genes involved in the PGE pathway (COX-1, or the PGE receptors) were not responsive to the treatment. None of the studied genes were affected by any CaSR agonist in GFP-only transfected HT29 and Caco-2 cells, indicating that the observed gene-inducing effects of spermine and -568 were indeed mediated by the CaSR. , we had previously determined that treatment with the clinically approved calcimimetic cinacalcet worsened symptoms in a dextran sulfate sodium (DSS)-induced colitis mouse model. In the colons of these mice, cinacalcet significantly induced gene expression of PGES-2 and the EP3 receptor, but not COX-2; while NPS 2143 increased the expression of the PGE-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Importantly, neither treatment had any effect on the colons of non-DSS treated mice. Overall, we show that activation of the CaSR induces the PGE pathway, albeit with differing effects and . This may be due to the different microenvironment compared to , specifically the presence of a CaSR-responsive immune system. Since calcilytics inhibit ligand-mediated CaSR signaling, they may be considered for novel therapies against inflammatory bowel disease.